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provided it is propeObjective: In addition to hypersensitivity reactions to abacavir, HLA B5701 has been
associated with slow or nonprogression of HIV infection. We explored the effect of HLA
B5701 on CD4þ cell count and viral load in untreated patients and on responses to
nonabacavir-containing combination antiretroviral therapy (cART) in a large UK-based
cohort.
Design: Analysis of a cohort of HIV-infected adults.
Methods: In untreated patients, CD4þ cell count and viral load at study entry were
compared in HLAB5701-positive and HLAB5701-negative individuals and linear
regression tested for an interaction effect of viral load and HLA B5701 on CD4þ cell
count. In patients starting a nonabacavir cART regimen, Cox proportional hazards
models compared virological responses to cART among HLA B5701-negative, HLA
B5701-positive, and those not tested. Six-month and 12-month changes in CD4þ cell
count were used as outcomes in linear regression to compare immunological response
to cART in these groups.
Results: ART-naive HLA B5701-positive individuals had higher CD4þ cell count
(P<0.0001) and lower viral load (P<0.0001) at study entry than negatives; however,
HLA B5701 status was not found to effect the association between viral load and CD4þ
cell count (interaction P value¼0.09). HLA B5701-positive patients were more likely
to achieve viral suppression than negative patients on a nonabacavir regimen [hazard
ratio¼1.29, 95% confidence interval, CI (1.15–1.54)] and less likely to experience
viral rebound [hazard ratio¼0.61, 95% CI (0.37–0.99)].
Conclusion: Better virological but not immunological responses to cART were seen in
HLA B5701-positive patients on nonabacavir regimens. This study provides further
evidence of the potentially beneficial effect of HLA B5701 on HIV progression.
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The HLA allele B5701 is strongly associated with
hypersensitivity reactions to abacavir [1–4]. Hence, most
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the HLA B5701 allele has also been found to be more
common in HIV ‘slow progressors’ or ‘nonprogressors’
[6–8]. It is hypothesized that protection occurs through
more effective HLA class I T-lymphocyte responses
to HIV-1 antigens with less mutational escape leading
to better control of viral replication and lower viral loads
[7–12]. Previous studies exploring the influence of HLA
B5701 on disease progression have been relatively small
[6–8]; none have explored the effect of this allele on the
relationship between HIV viral load and CD4þ cell count
in untreated individuals and few have assessed its influence
on the response to antiretroviral therapy (ART) [13,14].
We explored the effect of HLA B5701 status on both of
these parameters in a large UK cohort.Methods
The UK Collaborative HIV Cohort (UK CHIC) study
collates data collected routinely as part of HIV care from
several large HIV centers across the UK [15]. Data items
collected include demographics, CD4þ cell count and
HIV viral load, ART history, AIDS-defining events,
laboratory markers, and HLA B5701 testing. The
current dataset contains information on patients from
15 centers, of which, four did not provide data on HLA
B5701 testing. There were two aspects to this study: to
investigate the effect of a positive HLA B5701 status on
viral load and CD4þ cell count in untreated individuals
and to compare response to combination antiretroviral
therapy (cART) in those positive and negative for the
allele. Individuals tested for HLA B5701 were included
in the first aspect of this study if they were found to have
been ART-naive upon entry into the UK CHIC study,
regardless of when the test was performed. If, follow-
ing their test, participants went on to commence a
nonabacavir cART regimen, they were eligible to be
included in the comparison of virological and immuno-
logical treatment responses according to HLA B5701
status. Individuals who were not tested and who started a
nonabacavir regimen after 2005 when HLA B5701
testing became routine were also included for comparison
with the HLA B5701-negative individuals. A non-
abacavir cART regimen was defined as any regimen
combining at least three antiretroviral drugs, none of
which were abacavir. Mono and dual-therapy regimens
were not classed as cART. Analyses were performed in
all patients starting a nonabacavir regimen as previously
stipulated and in a subgroup of individuals who were
ART-naive at the time of starting the regimen.
Continuous variables were compared using Wilcoxon
rank-sum tests or t-tests and x2 tests compared categorical
variables according to HLA B5701 status. The effect of
viral load and HLA B5701 status on CD4þ cell count in
untreated individuals were assessed using linear regressionpyright © Lippincott Williams & Wilkins. Unauthoadjusted for sex, age (per 10 years), and ethnic group
(white, black African, black other, other). An interaction
between viral load and HLA B5701 status was then tested
in the regression model to determine whether the effect
of viral load on CD4þ cell count differed in those
who were positive for the allele and those negative.
A subanalysis was performed only in those of white
ethnicity and the analysis was repeated as a sensitivity
analysis using generalized estimating equations (GEEs) to
analyze all off-ART CD4þ cell count and viral load
pairs, taking into account within-subject correlation.
Cox Proportional Hazards Models compared virological
response to a nonabacavir regimen in HLA B5701-
negative individuals to that in HLA B5701-positive
individuals and those who had not been tested for the
allele. Outcomes assessed were time to undetectable viral
load (first viral load<50 copies/ml), viral rebound
(the first of two consecutive viral loads>50 copies/ml
in those who had achieved undetectable viral load),
and treatment switch. Covariates adjusted for were sex;
ethnicity (white, black, other); exposure (homo/bisexual,
heterosexual, other); age (per 10 years); viral load at
regimen start (log10copies/ml); CD4
þ cell count at
regimen start (per 50 cells/ml); nonabacavir regimen
class (protease inhibitor-based, non-nucleoside reverse
transcriptase inhibitor-based, nucleoside reverse tran-
scriptase inhibitor only, other); hepatitis B virus/hepatitis
C virus (HCV) coinfection (no, yes, not tested); and,
wherein ART-experienced patients were included, the
number of previous regimens (0, 1–5, 6–10, >10)
and any previous virological failures (no, yes). Linear
regression assessed immunological response to cART
according to HLA B5701 status, with both 6-month and
12-month change in CD4þ cell count from regimen start
used as outcomes. Models were adjusted for sex, ethnicity,
exposure, age, viral load, and CD4þ cell count at regimen
start, nonabacavir regimen class, HCV coinfection,
number of previous regimens, and any previous viro-
logical failure.Results
A total of 8246 patients in the UK CHIC study had ever
received a HLA B5701 test, of whom 426 (5.2%) were
positive. There were 3258 patients ever tested who
were ART-naive at study entry and who were included in
the study of the effects of HLA B5701 status and viral
load on CD4þ cell count; 165 (5.1%) of this group had
tested positive for HLA B5701. Characteristics of these
patients are given in Table 1(i). Median (interquartile
range, IQR) CD4þ cell count at entry was 511 (365–
663) cells/ml in HLA B5701-positive individuals and
395 (282–540) cells/ml in HLA B5701-negative
(P<0.0001). Median (IQR) viral load at study entry
was 4.1 (3.3–4.6) and 4.5 (3.9–5.0) log10 copies/ml in
those positive and negative, respectively (P<0.0001).rized reproduction of this article is prohibited.
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Table 1. Characteristics of patients included in each aspect of study.
(i) Patients ever tested who were
untreated at study entry (n¼3258)









negative Not tested P
N (%) 165 (5.1) 3093 (94.9) 220 (2.3) 2981 (31.2) 6364 (66.5)
ART-naive – – – 89 (40.5) 1393 (46.7) 2157 (33.9) <0.0001
Age [median (IQR)] 34 (29–40) 34 (28–40) 0.28 43 (37–50) 39 (33–46) 41 (35–47) <0.0001
Sex
Male 140 (84.8) 2259 (73.0) 0.001 192 (87.3) 2022 (67.8) 4538 (71.3) <0.0001
Ethnicity
White 127 (77.0) 1676 (54.2) <0.0001 161 (73.2) 1407 (47.2) 3402 (53.5) <0.0001
Black African 15 (9.1) 846 (27.4) 17 (7.7) 1044 (35.0) 1876 (29.5)
Black other 7 (4.2) 208 (6.7) 12 (5.5) 223 (7.5) 316 (5.0)
Other 16 (9.7) 363 (11.7) 30 (13.6) 307 (10.3) 770 (12.1)
Exposure
MSM 123 (74.5) 1700 (55.0) <0.0001 161 (73.2) 1352 (45.4) 3235 (50.8) <0.0001
Heterosexual 34 (20.6) 1217 (39.4) 47 (21.4) 1393 (46.7) 2614 (41.1)
Other/unknown 8 (4.9) 176 (5.7) 12 (5.5) 236 (7.9) 515 (8.1)
Hepatitis B coinfection
No 82 (49.7) 1725 (55.8) 0.034 162 (73.6) 2134 (71.6) 3762 (59.1) <0.0001
Yes 0 (0.0) 62 (2.0) 5 (2.3) 133 (4.5) 311 (4.9)
No test/unknown 83 (50.3) 1306 (42.2) 53 (24.1) 714 (24.0) 2291 (36.0)
Hepatitis C coinfection
No 88 (53.3) 1749 (56.5) 0.53 161 (73.2) 2036 (68.3) 3788 (60.1) <0.0001
Yes 4 (2.4) 101 (3.3) 11 (5.0) 153 (5.1) 317 (5.5)
No test/unknown 73 (44.2) 1243 (40.2) 48 (21.8) 792 (26.6) 2259 (34.4)
Year of entry
Prior to 2004 69 (41.8) 1197 (38.7) 0.48 146 (66.4) 1393 (46.7) 4043 (63.5) <0.0001
2005–2007 52 (31.5) 1119 (36.2) 48 (21.8) 879 (29.5) 1164 (18.3)
2008–2011 44 (26.7) 777 (25.1) 26 (11.8) 709 (23.8) 1157 (18.2)
Previous AIDS
Yes 11 (6.7) 290 (9.4) 0.24 38 (17.2) 537 (18.0) 1468 (23.1) <0.0001
CD4þ cell count cells/ml
[Median (IQR)] 511 (365–663) 395 (282–540) <0.0001 319 (209–515) 300 (198–460) 350 (220–559) <0.0001
Viral load log10 copies/ml
[Median (IQR)] 4.1 (3.3–4.6) 4.5 (3.9–5.0) <0.0001 2.9 (1.7–4.6) 3.9 (1.7–4.9) 1.8 (1.7–4.5) <0.0001
(i) Characteristics for this patient group are calculated at study entry; (ii) characteristics for this patient group are calculated upon commencement
of nonabacavir combination antiretroviral therapy (cART) regimen.In linear regression, both HLA B5701 status and viral
load were independently associated with CD4þ cell count
at entry after adjustment for age, sex, and ethnicity, with a
mean (95% confidence interval, CI) CD4þ cell count
increase of 42 (10–74) cells/ml in HLA B5701-positive
individuals over negative and an 80 (72–88) cells/ml
decrease for every log10 copy increase in viral load (results
not shown). However, a test for an interaction between
HLA B5701 status and viral load did not suggest
strong evidence that viral load had a differential impact
on CD4þ cell count in those who were positive for the
allele and those negative (P¼ 0.088). Further, in linear
regression models of all off-ART CD4þ and viral load
pairs and models restricted to those of white ethnicity,
there was no evidence of an interaction between viral
load and HLA B5701 status (P¼ 0.76 and P¼ 0.95,
respectively).
There were 3476 tested individuals who commenced
a nonabacavir cART regimen following a test for
HLA B5701, 3201 of whom had follow-up of at least
one CD4þ cell count and viral load measurement.Copyright © Lippincott Williams & Wilkins. UnautA further 6364 individuals who had not been tested
commenced a nonabacavir regimen after 2005. Charac-
teristics of all 9565 patients upon starting a nonabacavir
regimen are shown in Table 1(ii). In the subgroup of
ART-naive patients, HLA B5701-positive individuals
were more likely to achieve an undetectable viral load
than negative [adjusted hazard ratio (AHR)¼ 1.60, 95%
CI (1.28–2.01) (Table 2)]. HLA B5701-positive patients
also showed a decreased likelihood of experiencing viral
rebound compared with negatives, although this result
did not reach statistical significance [AHR¼ 0.57, 95%
CI (0.23–1.39)]. There was a small reduction in the risk
of treatment switch that was not significant [AHR¼ 0.86,
95% CI (0.60–1.22)]. Those not tested had a similar risk
of viral rebound and treatment switch to HLA B5701
negatives, but a slightly increased likelihood of achieving
an undetectable viral load (hazard ratio¼ 1.15, 95% CI
1.06–1.24). Including ART-experienced patients in
the analysis of virological response yielded similar
results (Table 2). An increased likelihood of viral
suppression was still present in positive patients compared
with negative [AHR¼ 1.29, 95% CI (1.15–1.54)], as washorized reproduction of this article is prohibited.
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Negative 1.00 – – 1.00 – –
Positive 1.50 (1.21–1.87) 0.0003 1.60 (1.28–2.01) <0.0001
Not tested 0.96 (0.89–1.03) 0.29 1.15 (1.06–1.24) 0.001
Viral load rebound Negative 1.00 – – 1.00 – –
Positive 0.44 (0.18–1.08) 0.073 0.57 (0.23–1.39) 0.22
Not tested 0.95 (0.77–1.17) 0.63 0.90 (0.72–1.13) 0.37
Treatment switch Negative 1.00 – – 1.00 – –
Positive 0.72 (0.51–1.02) 0.063 0.86 (0.60–1.22) 0.39











All patients Viral load
<50 copies/ml
Negative 1.00 – – 1.00 – –
Positive 1.45 (1.26–1.67) <0.0001 1.29 (1.15–1.54) 0.0005
Not tested 1.01 (0.97–1.06) 0.59 0.97 (0.92–1.01) 0.15
Viral load rebound Negative 1.00 – – 1.00 – –
Positive 0.47 (0.29–0.77) 0.003 0.61 (0.37–0.99) 0.044
Not tested 0.91 (0.81–1.04) 0.15 0.87 (0.77–1.00) 0.044
Treatment switch Negative 1.00 – – 1.00 – –
Positive 0.80 (0.66–0.98) 0.030 0.91 (0.74–1.12) 0.38
Not tested 1.03 (0.96–1.09) 0.43 0.98 (0.92–1.05) 0.60
ART, antiretroviral therapy.
aAdjusted for viral load, CD4þ cell count, regimen type, age, hepatitis B and C coinfection at regimen start and sex, ethnicity, and exposure group.
bAdjusted for viral load, CD4þ cell count, regimen type, age, hepatitis B and C coinfection, number of previous regimens and any previous
virological failure at regimen start and sex, ethnicity, and exposure group.the decreased risk of viral rebound, which was now
significant [AHR¼ 0.61, 95% CI (0.37–0.99)] due to the
larger number of individuals included in the analysis.
Immunological response to cART did not differ
according to HLA B5701 status. Being HLA B5701-
positive increased 6-month CD4þ cell count change
by 16.7 cells/ml [95% CI (11.5–45.0)] on average
compared with the 6-month change in negative patients.
Twelve-month CD4þ cell count change was in fact lower
by approximately 28 cells/ml [95% CI (62.3–5.8)] in
positive patients compared with negative. There was no
difference in 6-month [b¼10.6, 95% CI (20.0–1.2)]
or 12-month [b¼ 1.2, 95% CI (10.5–12.9)] CD4þ cell
count change between those negative and those not tested
for the allele.Discussion
To our knowledge, this is the first large study of a
representative HIV-infected population to assess the
influence of HLA B5701 status on virological outcomes
and immunological response to cART. When treated
with nonabacavir-containing cART and after adjustment
for baseline viral load, HLA B5701-positive patients
were more likely to achieve an undetectable viral load,
and less likely to experience viral load rebound than
HLA B5701-negative individuals. This is the first studypyright © Lippincott Williams & Wilkins. Unauthoto indicate a beneficial effect of HLA B5701 on
achieving and maintaining viral load suppression.
Interestingly, the only other study assessing virological
outcomes, the female WIHS Cohort (some of whom
were treated with abacavir), showed poorer virological
responses in those with HLA B5701 [14]. Previous
studies, like ours, failed to show any effect of HLA B5701
on CD4þ cell recovery after starting ART [13,14].
A possible mechanism for our findings may be that the
allele provides a more effective immunological (cytotoxic
T lymphocyte) response to augment the effect of ART
in diminishing cells that support active viral repli-
cation [13,14,16]. Our finding of improved virological
outcomes in HLA B5701-positive individuals requires
confirmation in other large cohorts.
Our data also demonstrate that HLA B5701-positive
individuals had a significantly higher CD4þ cell count
and lower viral load at presentation compared with
HLA B5701-negative patients. The observation that
HLA B5701-positive individuals had improved markers
of HIV disease over HLA B5701-negative individuals
at study entry is consistent with slower HIV disease
progression in this group, which has been seen in other
studies [6,7,14]. However, a main limitation of this study
is that this hypothesis could not be confirmed, as data
on the likely date of HIV infection were not available.
Another limitation of this study is the relatively small
numbers of HLA B5701-positive individuals in some
analyses. We did not assess rate of CD4þ cell declinerized reproduction of this article is prohibited.
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HIV disease progression in our untreated patient group.
In an observational cohort such as this that utilizes only
clinical data, we are unlikely to attain sufficient pre-ART
CD4þ cell data to achieve reliable results from an analysis
of this kind. Further work to assess CD4þ cell count
decline from time of HIV seroconversion in untreated
HLA B5701-positive and negative individuals is needed.
In conclusion, we have found that HLA B5701 status
may affect CD4þ cell count, HIV viral load, and responses
to cART. This is further evidence that the HLA B5701
allele may be beneficial in terms of slower progression of
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